Intravitreal dexamethasone as an enhancer for the anti-VEGF treatment in neovascular ARMD: Recovering an old ally
Dexametasona intravítrea como potenciador del tratamiento anti-VEGF en la degeneración macular asociada a la edad neovascular: recuperando un viejo aliado
R. Gallego-Pinazoa, C. Marín-Lambíesa, F. Marín-Olmosb, R. Martínezb, R. Fonsc, M.L. Díaz-Llopisa,d,e
a Ophthalmology Service, University Hospital La Fe, Valencia, Spain
b Ophthalmology Service, University Clinic Hospital, Valencia, Spain
c Ophthalmology Service, Lluís Alcanyís Hospital, Xàtiva, Valencia, Spain
d Medicine College, University of Valencia, Spain
e Biomedical Research Centre in the Rare Diseases Network (CIBERER), Valencia, Spain
Read
453
Timeswas read the article
278
Total PDF
175
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 31 | 0 | 31 |
| 2025 11 | 0 | 8 | 8 |
| 2025 10 | 0 | 1 | 1 |
| 2025 9 | 0 | 5 | 5 |
| 2025 8 | 0 | 11 | 11 |
| 2025 7 | 0 | 4 | 4 |
| 2025 6 | 0 | 2 | 2 |
| 2025 5 | 0 | 1 | 1 |
| 2025 3 | 0 | 2 | 2 |
| 2025 2 | 0 | 1 | 1 |
| 2025 1 | 0 | 2 | 2 |
| 2024 12 | 0 | 2 | 2 |
| 2024 11 | 0 | 7 | 7 |
| 2024 10 | 0 | 9 | 9 |
| 2024 9 | 0 | 14 | 14 |
| 2024 8 | 0 | 12 | 12 |
| 2024 7 | 0 | 7 | 7 |
| 2024 6 | 0 | 7 | 7 |
| 2024 5 | 0 | 3 | 3 |
| 2024 4 | 0 | 2 | 2 |
| 2024 3 | 0 | 4 | 4 |
| 2024 2 | 0 | 1 | 1 |
| 2024 1 | 0 | 3 | 3 |
| 2023 11 | 0 | 3 | 3 |
| 2023 10 | 0 | 4 | 4 |
| 2023 8 | 0 | 3 | 3 |
| 2023 7 | 0 | 4 | 4 |
| 2023 6 | 0 | 1 | 1 |
| 2023 5 | 0 | 1 | 1 |
| 2023 4 | 0 | 1 | 1 |
| 2023 3 | 2 | 1 | 3 |
| 2023 1 | 0 | 2 | 2 |
| 2022 12 | 0 | 4 | 4 |
| 2022 11 | 0 | 2 | 2 |
| 2022 10 | 0 | 3 | 3 |
| 2022 9 | 0 | 7 | 7 |
| 2022 8 | 0 | 5 | 5 |
| 2022 7 | 0 | 1 | 1 |
| 2022 5 | 0 | 4 | 4 |
| 2022 4 | 0 | 1 | 1 |
| 2022 3 | 0 | 4 | 4 |
| 2022 2 | 0 | 1 | 1 |
| 2022 1 | 0 | 1 | 1 |
| 2021 12 | 0 | 5 | 5 |
| 2021 11 | 0 | 5 | 5 |
| 2021 10 | 0 | 4 | 4 |
| 2021 9 | 0 | 4 | 4 |
| 2021 8 | 0 | 1 | 1 |
| 2021 7 | 0 | 3 | 3 |
| 2021 6 | 0 | 3 | 3 |
| 2021 5 | 0 | 1 | 1 |
| 2021 4 | 0 | 8 | 8 |
| 2021 2 | 0 | 1 | 1 |
| 2021 1 | 0 | 1 | 1 |
| 2020 12 | 0 | 1 | 1 |
| 2020 11 | 0 | 1 | 1 |
| 2020 10 | 0 | 1 | 1 |
| 2020 7 | 0 | 1 | 1 |
| 2020 4 | 0 | 1 | 1 |
| 2020 3 | 0 | 1 | 1 |
| 2020 1 | 0 | 1 | 1 |
| 2019 12 | 0 | 2 | 2 |
| 2019 11 | 0 | 1 | 1 |
| 2019 9 | 0 | 5 | 5 |
| 2019 6 | 0 | 1 | 1 |
| 2019 5 | 0 | 20 | 20 |
| 2018 12 | 0 | 2 | 2 |
| 2018 2 | 0 | 2 | 2 |
| 2017 12 | 1 | 1 | 2 |
| 2017 11 | 2 | 1 | 3 |
| 2017 10 | 1 | 4 | 5 |
| 2017 9 | 2 | 4 | 6 |
| 2017 8 | 1 | 0 | 1 |
| 2017 7 | 3 | 3 | 6 |
| 2017 6 | 9 | 1 | 10 |
| 2017 5 | 14 | 11 | 25 |
| 2017 4 | 7 | 2 | 9 |
| 2017 3 | 17 | 9 | 26 |
| 2017 2 | 13 | 1 | 14 |
| 2017 1 | 5 | 0 | 5 |
| 2016 12 | 24 | 1 | 25 |
| 2016 11 | 12 | 0 | 12 |
| 2016 10 | 17 | 2 | 19 |
| 2016 9 | 7 | 1 | 8 |
| 2016 8 | 6 | 0 | 6 |
| 2016 7 | 1 | 0 | 1 |
Show all
